Zydus Lifesciences buys Assertio for over ₹1,590cr; NASDAQ delisted
Business
Zydus Lifesciences has snapped up U.S.-based Assertio Holdings for $166.4 million (over ₹1,590 crore).
The deal was made through wholly-owned subsidiary, Zara Merger Sub Inc., and now Assertio is fully part of the Zydus family: its shares have also been taken off Nasdaq.
Assertio brings specialty and cancer-supportive expertise
Assertio brings expertise in specialty and cancer-supportive medicines.
The company sees this as a smart step toward future growth in the pharmaceutical world.